The paper's citation list
No. | The paper's citation list |
|---|
1 | Targeted therapies in ameloblastomas and amelobastic carcinoma—A systematic review. 2024;30:3571 doi: 10.1111/odi.14962 |
2 | ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer. 2022;13: doi: 10.3389/fgene.2022.966365 |
3 | HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond. 2024; doi: 10.20517/cdr.2024.103 |
4 | IQ Motif Containing GTPase Activating Proteins (IQGAPs), A-Kinase Anchoring Proteins (AKAPs) and Kinase Suppressor of Ras Proteins (KSRs) in Scaffolding Oncogenic Pathways and Their Therapeutic Potential. 2022;7:45837 doi: 10.1021/acsomega.2c05505 |
5 | Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers. 2025; doi: 10.20517/cdr.2024.125 |
6 | Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1H-benzo[d]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the “Clamp” Strategy. 2024;67:15246 doi: 10.1021/acs.jmedchem.4c00860 |
7 | Remodeling tumor microenvironment with natural products to overcome drug resistance. 2022;13: doi: 10.3389/fimmu.2022.1051998 |
8 | Metastasiertes nichtkleinzelliges Lungenkarzinom: Zielgerichtete Therapie – was uns in der Zukunft erwartet. 2023; doi: 10.3238/PersOnko.2023.03.03.02 |
9 |
Exploiting c-RAF dependency in RAS mutant cancer:
beyond catalytic activity
. 2024;24:95 doi: 10.1080/14737140.2024.2319035 |
10 | Preclinical Evaluation of a Radiolabeled Pan-RAF Inhibitor for RAF-Specific PET/CT Imaging. 2024;21:5247 doi: 10.1021/acs.molpharmaceut.4c00649 |
11 | Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?. 2023;12: doi: 10.3389/fonc.2022.1074726 |
12 | A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy. 2025;109 doi: 10.1002/9781119834090.ch3 |
